Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Generics Account for 18% of Drug Cost at a Yokohama Hospital
January 26, 2009
- SELF-MEDICATION NEWS IN BRIEF
January 26, 2009
- Review of Febuxostat by FDA to Be Extended
January 26, 2009
- Revised Version of Hypertension Treatment GL Issued
January 26, 2009
- 2 Anti-HIV Drugs Included in NHI Drug Price List
January 26, 2009
- Draft GL on Peritoneal Dialysis Published: JSDT
January 26, 2009
- NHI Prices of Novoseven Re-Priced Upward due to Unprofitability
January 26, 2009
- Series of Tamiflu-Resistant Viruses Detected
January 26, 2009
- JPMA Creates Project Team to Promote Development of Unapproved Drugs, Indications
January 26, 2009
- Medical Fees Grew 2.2% in 1st Half of FY2008
January 26, 2009
- JPO Considers Extension of Patent Periods for DDS Formulations
January 26, 2009
- Total Fee Points Up 0.7% at Psychiatric Hospitals
January 26, 2009
- R&D NEWS IN BRIEF
January 26, 2009
- Kyowa Kirin to Develop KW-6002 in Japan by Itself, License It Out Overseas
January 26, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 26, 2009
- REGULATORY NEWS IN BRIEF
January 26, 2009
- Ranbaxy to Join Daiichi Sankyo to Market Olmesartan in India
January 26, 2009
- Novartis to Start Global PIII Trial of Everolimus for Stomach Cancer Based on POC Established in Japan
January 26, 2009
- Taisho Ties Up with GSK to Commercialize Xenical in Japan
January 26, 2009
- Biosimilars Are Likely to Be Developed by Research-Driven Companies in Japan: Ihoken
January 26, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…